- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Heterogeneity of claudin 18.2 expression in metastatic gastric cancer ; volume:14 ; number:1 ; day:31 ; month:7 ; year:2024 ; pages:1-9 ; date:12.2024
Scientific reports ; 14, Heft 1 (31.7.2024), 1-9, 12.2024
- Creator
-
Choi, Eugene
Shin, Jinho
Ryu, Min-Hee
Kim, Hyung-Don
Park, Young Soo
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-68411-w
- URN
-
urn:nbn:de:101:1-2410250848225.533760406762
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Choi, Eugene
- Shin, Jinho
- Ryu, Min-Hee
- Kim, Hyung-Don
- Park, Young Soo
- SpringerLink (Online service)
Other Objects (12)
Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas
Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
Claudin-18.2 mediated interaction of gastric Cancer cells and Cancer-associated fibroblasts drives tumor progression
Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer
Clinicopathological significance of claudin-4 in gastric carcinoma
Temporal heterogeneity of HER2 expression in metastatic gastric cancer: a case report
Immunohistochemical profiles of claudin-3 in primary and metastatic prostatic adenocarcinoma
Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study
Personalisierte Therapieoptionen beim Ösophaguskarzinom - Relevanz der Expression von Mesothelin und Claudin 18.2
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting
MiRNA-182-5p aggravates experimental ulcerative colitis via sponging Claudin-2
Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas
Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
Claudin-18.2 mediated interaction of gastric Cancer cells and Cancer-associated fibroblasts drives tumor progression
Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer
Clinicopathological significance of claudin-4 in gastric carcinoma
Temporal heterogeneity of HER2 expression in metastatic gastric cancer: a case report
Immunohistochemical profiles of claudin-3 in primary and metastatic prostatic adenocarcinoma
Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study
Personalisierte Therapieoptionen beim Ösophaguskarzinom - Relevanz der Expression von Mesothelin und Claudin 18.2
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting
MiRNA-182-5p aggravates experimental ulcerative colitis via sponging Claudin-2
Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas
Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
Claudin-18.2 mediated interaction of gastric Cancer cells and Cancer-associated fibroblasts drives tumor progression
Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer
Clinicopathological significance of claudin-4 in gastric carcinoma
Temporal heterogeneity of HER2 expression in metastatic gastric cancer: a case report
Immunohistochemical profiles of claudin-3 in primary and metastatic prostatic adenocarcinoma
Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study
Personalisierte Therapieoptionen beim Ösophaguskarzinom - Relevanz der Expression von Mesothelin und Claudin 18.2
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting